Sangamo Therapeutics Sees Unusually High Options Volume (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of unusually large options trading on Thursday. Stock traders bought 11,512 call options on the stock. This is an increase of 460% compared to the typical volume of 2,054 call options.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System increased its holdings in shares of Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $89,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sangamo Therapeutics during the 1st quarter valued at approximately $331,000. Finally, Marshall Wace LLP boosted its holdings in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 207,476 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on SGMO. StockNews.com began coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They set a “sell” rating for the company. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $2.67.

Sangamo Therapeutics Stock Up 7.5 %

Shares of NASDAQ:SGMO opened at $0.90 on Friday. The business’s 50-day moving average is $0.76 and its 200 day moving average is $0.65. Sangamo Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The company had revenue of $0.36 million for the quarter, compared to analyst estimates of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. On average, equities research analysts predict that Sangamo Therapeutics will post -0.47 EPS for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.